Fungal infections in bone marrow transplant patients

Current Opinion in Infectious Diseases

Volumn 17, Issue 4, 2004, Pages 347-352

  Brown, Janice M Y ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungal immune response; Antifungal resistance; Graft versus host disease; Hematopoietic cell transplantation; Invasive fungal infection; Nonmyeloablative preparative regimen; Prophylaxis

Indexed keywords

AMINOTRANSFERASE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CALCINEURIN INHIBITOR; CASPOFUNGIN; CYCLOSPORIN; CYTOCHROME P450; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; STEROID; VORICONAZOLE;

ADOPTIVE IMMUNOTHERAPY; AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; ASPERGILLUS; BILIRUBIN BLOOD LEVEL; BONE MARROW; BONE MARROW TRANSPLANTATION; CANDIDA; CANDIDIASIS; CHAETOMIUM; CREATININE BLOOD LEVEL; DENDRITIC CELL; DRUG TOLERANCE; ENZYME INHIBITION; FUNGUS GROWTH; GASTROINTESTINAL SYMPTOM; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE; MYCOSIS; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD STEM CELL; POLYMERASE CHAIN REACTION; REVIEW; TREATMENT FAILURE;

ANTIFUNGAL AGENTS; BONE MARROW TRANSPLANTATION; FLUCONAZOLE; FUNGEMIA; HUMANS; IMMUNOCOMPROMISED HOST;

EID: 3843142759     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000136935.13662.af     Document Type: Review

References (53)

1. Antoniadou A, Kontoyiannis DP. Status of combination therapy for refractory mycoses. Curr Opin Infect Dis 2003; 16:539-545. An excellent and balanced review of the in-vitro and limited clinical data regarding combination therapy.
2. Jones BL, McLintock LA. Impact of diagnostic markers on early antifungal therapy. Curr Opin Infect Dis 2003; 16:521-526.
3. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 2003; 16:607-612.
4. Rovira M, Jimenez M, De La Bellacasa JP, et al. Detection of Aspergillus galactomannan by enzyme immunoabsorbent assay in recipients of allogeneic hematopoietic stem cell transplantation: a prospective study. Transplantation 2004; 77:1260-1264.
5. Viscoli C, Machetti M, Cappellano P, et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin- tazobactam. Clin Infect Dis 2004; 38:913-916.
6. Sulahian A, Touratier S, Ribaud P. False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003; 349:2366-2367. Although narrow in scope, clinicians with limited experience with this test may find this helpful in interpreting the results of the test with known inter- and intraspecimen variability.
7. Kawazu M, Kanda Y, Goyama S, et al. Rapid diagnosis of invasive pulmonary aspergillosis by quantitative polymerase chain reaction using bronchial lavage fluid. Am J Hematol 2003; 72:27-30.
8. Gulbahce HE, Pambuccian SE, Jessurun J, et al. Pulmonary nodular lesions in bone marrow transplant recipients: impact of histologic diagnosis on patient management and prognosis. Am J Clin Pathol 2004; 121:205-210.
9. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med 2003; 138:705-713. This is the first study with a reasonable cohort of patients that demonstrated statistically significant reduction in mold infections in the group that received itraconazole prophylaxis, although it is notable that breakthrough mold infections continued to occur.
10. Marr KA, Leisenring W, Grippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103:1557-1559. These observations will help raise awareness of potential drug interaction.
11. Tran HA, Vincent JM, Slavin MA, Grigg A. Esophageal perforation secondary to angio-invasive Candida glabrata following hemopoietic stem cell transplantation. Clin Microbiol Infect 2003; 9:1215-1218,
12. Antoniadou A, Torres HA, Lewis RE, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 2003; 82:309-321.
13. Marco F, Danes C, Almela M, et al. Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates: results from a six-year study (1996-2001). Diagn Microbiol Infect Dis 2003; 46:259-264.
14. Mossad SB. Prevention and treatment of fungal infections in bone marrow transplantation. Curr Hematol Rep 2003; 2:302-309.
15. Marchetti O, Bille J, Fluckiger U, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004; 38:311-320.
16. Pfaller MA, Messer SA, Boyken L, et al. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J Clin Microbiol 2003; 41:2176-2179.
17. Avivi I, Oren I, Haddad N, et al. Stem cell transplantation post invasive fungal infection is a feasible task. Am J Hematol 2004; 75:6-11.
18. Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33:943-948.
19. Eibl M, Auner HW, Zinke-Cerwenka W, et al. High-risk AML complicated by pulmonary aspergillosis: successful treatment with nonmyeloablative stem cell transplantation and long-term administration of voriconazole. Ann Hematol 2004; 83:133-136.
20. Mohammedi I, Piens MA, Audigier-Valette C, et al. Fatal Microascus trigonosporus (Anamorph Scopulariopsis) pneumonia in a bone marrow transplant recipient. Eur J Clin Microbiol Infect Dis 2004; 23:215-217.
21. Teixeira AB, Trabasso P, Moretti-Branchini ML, et al. Phaeohyphomycosis caused by Chaetomium globosum in an allogeneic bone marrow transplant recipient. Mycopathologia 2003; 156:309-312.
22. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350:950-952.
23. Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003; 22:111-113.
24. Rodriguez CA, Lujan-Zilbermann J, Woodard P, et al. Successful treatment of disseminated fusariosis. Bone Marrow Transplant 2003; 31:411-412.
25. Novicki TJ, LaFe K, Bui L, et al. Genetic diversity among clinical isolates of Acremonium strictum determined during an investigation of a fatal mycosis. J Clin Microbiol 2003; 41:2623-2628.
26. Walsh TJ, Petraitis V, Petraitiene R, et al. Experimental pulmonary aspergillosls due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 2003; 188:305-319. A well written review of the biology of an emerging pathogen, notable for its resistance to amphotericin.
27. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122-1131.
28. Baden LR. Prevention and therapy of fungal infections in bone marrow transplantation. Leukemia 2003; 17:1038-1041.
29. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187:1834-1843.
30. Graybill JR, Bocanegra R, Gonzalez GM, Najvar LK. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J Antimicrob Chemother 2003; 52:656-662.
31. Graybill JR, Bocanegra R, Najvar LK, et al. Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis. Antimicrob Agents Chemother 2003; 47:2373-2375.
32. Steinbach WJ, Schell WA, Blankenship JR, et al. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother 2004; 48:1664-1669.
33. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004; May 3 [Epub ahead of print].
34. Gow KW, Hayes-Jordan AA, Billups CA, et al. Benefit of surgical resection of invasive pulmonary aspergillosis in pediatric patients undergoing treatment for malignancies and immunodeficiency syndromes. J Pediatr Surg 2003; 38:1354-1360. This small series reiterates the potential benefit of surgical resection in the treatment of invasive aspergillosis.
35. Yanada M, Yamamoto K, Emi N, et al. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 32:801-807.
36. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102:827-833.
37. Mohty M, Jacot W, Faucher C, et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003; 17:2168-2177.
38. Hagen EA, Stern H, Porter D, et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 2003; 36:9-15. These three studies confirm that the rates of IFI following nonmyeloablative and myeloablative preparative regimens are comparable. Moreover, GVHD and corticosteroid use are the key risk factors regardless of preparative regimen.
39. Tanimoto TE, Kusumi E, Hamaki T, et al. High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma. Bone Marrow Transplant 2003; 32:131-137.
40. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102:756-762. Nonmyeloablative preparative regimens have been reported to be associated with late GHVD. As IFIs are highly associated with GVHD, these data help inform clinical assessments of risk and the design of antifungal protocols. More importantly, by understanding how the preparative regimen influences the nature of immune reconstitution, specific risk factors for IFI may be uncovered.
41. Busca A, Locatelli F, Barbui A, et al. Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2003; 5:132-139.
42. Feinstein LC, Sandmaier BM, Maloney DG, et al. Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. Biol Blood Marrow Transplant 2003; 9:266-272.
43. Nakajima H, Oki M, Kishi K, et al. Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies. Clin Lab Haematol 2003; 25:383-391.
44. Daly A, McAfee S, Dey B, et al. Nonmyeloablative bone marrow transplantation: infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant 2003; 9:373-382.
45. Anderson D, DeFor T, Burns L, et al. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections. Biol Blood Marrow Transplant 2003; 9:52-59.
46. BitMansour A, Burns SM, Traver D, et al. Myeloid progenitors protect against invasive aspergillosis and Pseudomonas aeruginosa infection following hematopoietic stem cell transplantation. Blood 2002; 100:4660-4667.
47. Arber CA, BitMansour A, Brown JM. MHC-mismatched murine committed myeloid progenitors engraft and protect against invasive aspergillosis. Blood 2003; 102:941a. The enhanced reconstitution of functional antifungal immune response is not major histocompatibility complex-restricted. These observations expand the potential utility of enriching the allograft with myeloid progenitors, bridging chemotherapy-induced neutropenia, or infusions in genetic or acquired disorders of neutrophil deficiency.
48. Fernandez MN, Regidor C, Cabrera R, et al. Unrelated umbilical cord blood transplants in adults: early recovery of neutrophils by supportive co-transplantation of a low number of highly purified peripheral blood CD34+ cells from an HLA-haploidentical donor. Exp Hematol 2003; 31:535-544. The authors report the transient engraftment of haploidentical C34+ cells, which may serve as a bridge for the neutropenic period.
49. Wuthrich M, Filutowicz HI, Warner T, et al. Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts. J Exp Med 2003; 197:1405-1416. The plasticity of the nonmyeloid response is demonstrated in this model of murine fungal infection. Antigens of Blastomyces dermatrtidis or Histoplasma capsulatum were able to activate memory CD8+ cells in a major histocompatibility complex class-I manner even in the absence of CD4+ cells. CD8+ T cell-derived cytokines tumor necrosis factor-α, Interferon-γ, and granulocyte/macrophage colony-stimulating factor mediated durable vaccine immunity. Thus, a vaccine approach may be useful, even in a state of depleted lymphocyte populations that exists following HCT.
50. Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102:2768-2776. The anti-tumor necrosis factor-α antibody, Infliximab, was associated with a significant increase in IFI in patients with severe GVHD. This observation confirms that nonmyeloid responses are clinically significant with respect to the control of invasive rungal infection.
51. Montagnoli C, Bozza S, Bacci A, et al. A role for antibodies in the generation of memory antifungal immunity. Eur J Immunol 2003; 33:1193-1204.
52. Bozza S, Perruccio K, Montagnoli C, et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 2003; 102:3807-3814. Dendritic cells pulsed with conidia or transfected with conidial RNA activated T lymphocytes and enhance protection against aspergillosis in a murine model.
53. Morrison BE, Park SJ, Mooney JM, Mehrad B. Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis. J Clin Invest 2003; 112:1862-1870.